Why Attend the 11th Tumor Models Summit San Francisco?
Today's oncology leaders face increasing pressure to demonstrate clinical relevance earlier, justify R&D investment, and advance the right assets with confidence. Yet, as new modalities and model systems continue to emerge, determining the most effective path forward has become increasingly complex.
For many teams, the challenge is no longer access to models. It's understanding which models generate the evidence needed to confidently prioritize candidates, de-risk programs, and improve clinical predictability.
The 11th Tumor Models Summit San Francisco brings together the West Coast's leading discovery, translational, and preclinical decision-makers to evaluate the evidence, strategies, and technologies shaping oncology development. Focused on what drives better development decisions rather than technology alone, the meeting provides a dedicated forum to benchmark model selection approaches, strengthen candidate prioritization, and uncover what truly improves translational success.
Unmissable Event Highlights:
Building Confidence in Human-Relevant Models for Better Development Decisions
Explore how organoids, tumor cell systems, and tissue slice models can generate clinically relevant insights while overcoming validation challenges to strengthen translational confidence and support candidate progression decisions with Astellas
Optimizing Model Selection Across the Development Lifecycle
Understand how in vitro, cell-based, and in vivo model systems answer distinct biological, PK/PD, and translational questions to improve model selection confidence throughout the development lifecycle with Swiss Rockets
Applying AI Across Small Molecule & Antibody Discovery to Improve Candidate Selection
Explore how AI-enabled drug discovery approaches can improve target selection, molecule design, and candidate prioritization to generate stronger decision-making frameworks that reduce development risk and accelerate oncology R&D with Eli Lilly
What's New for 2027?
15%
New Discovery-Focused
Content to bridge the gap between target identification
and translational success
8
New Evidence & Insights Exchanges designed to move beyond presentations into real discussion and benchmarking
4+
New AI & Computational
Biology Case Studies
addressing candidate prioritization,
model selection, and
decision-making frameworks
New
Interactive Networking Formats connecting attendees facing similar modeling, modality, and translational challenges
Explore the Full Event Guide
- Explore the full agenda focused on clinical translation, model selection and development risk reduction
- Discover how leading oncology teams are evaluating organoids, ex vivo systems, AI-enabled platforms and in vivo models
- Preview case studies from Amgen, Astellas, Pfizer, Eli Lilly and emerging biotech innovators
- Benchmark approaches to biomarker development, resistance modeling, and candidate prioritization
- Connect with the leaders responsible for oncology development strategy, portfolio decisions, and preclinical investment
Attending Companies Included
Explore the Agenda
Discover how leading oncology teams are generating stronger evidence, improving translational confidence, and making better development decisions.
Partner With Us
Connect with the executives, heads, directors, and scientific leaders shaping oncology development strategy across the West Coast.
Join the Discussion
Benchmark your approach to model selection, candidate prioritization, resistance modeling, biomarker development, and translational decision-making.